GLP-1 vs GLP-2: Two Different Peptides Explained

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Searches for "GLP-1 vs GLP-2" reflect a real biological distinction — and a common point of confusion. GLP-1 (glucagon-like peptide-1) and GLP-2 (glucagon-like peptide-2) are two related but functionally distinct gut peptides. They are produced from the same proglucagon precursor and are co-secreted by intestinal L-cells, but their downstream effects, drug-development trajectories, and FDA-approval status are very different. This article covers what each is, what each is approved for, and the upstream genetic context as of April 2026.

What GLP-1 and GLP-2 actually are

GLP-1 is a 30- to 31-amino-acid peptide that drives glucose-dependent insulin release, slows gastric emptying, and signals satiety to the hypothalamus. GLP-2 is a 33-amino-acid peptide that promotes intestinal epithelial growth, enhances mucosal absorption, and supports gut barrier integrity. They share precursor biology but engage distinct receptors (GLP1R for GLP-1, GLP2R for GLP-2) with different downstream effects.

FDA-approved drugs in each class

GLP-1 receptor agonist medications include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound — also a GIP agonist), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). The only FDA-approved GLP-2 receptor agonist is teduglutide (Gattex), approved for short bowel syndrome — a very different therapeutic context. There is no overlap in clinical use.

Why people search "GLP-1 vs GLP-2"

The naming convention suggests a class with sequential members, but biologically these are distinct hormones from a shared precursor. The GLP-1 class is high-profile because of its role in type 2 diabetes and chronic weight management. GLP-2 occupies a small niche in gastrointestinal medicine. Conflating them in clinical decision-making is a category error — different peptides, different receptors, different indications.

Genetic context for the GLP-1 pathway

For the GLP-1 pathway specifically, variants in GLP1R, FTO, and MC4R sit upstream of every GLP-1 receptor agonist. GLP1R (the GLP-1 receptor gene itself; variants influence receptor density and downstream incretin signaling efficiency) is the most direct upstream variable. These variants do not predict response to any specific medication — they shape the metabolic terrain on which the GLP-1 class operates.

PlexusDx offers GLP-1 receptor agonist through its Weight Management Protocols, including Weight Management Protocols. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in GLP1R, FTO, MC4R, and TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: What Is GLP-1?, GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone.

Disclaimer: The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare formats inside the PlexusDx Weight Management Protocols collection, or start upstream with the Precision Peptide Genetic Test to understand your GLP-1 pathway biology before committing to a protocol.

Frequently Asked Questions

Are GLP-1 and GLP-2 the same thing?

No. GLP-1 and GLP-2 are distinct peptides cleaved from the same proglucagon precursor but acting on different receptors with different downstream effects. GLP-1 drives insulin secretion, satiety, and gastric emptying. GLP-2 supports intestinal mucosal growth and gut barrier function.

Is there a "GLP-2 medication" like Ozempic?

Teduglutide (Gattex) is the FDA-approved GLP-2 receptor agonist, indicated for short bowel syndrome — a niche gastrointestinal condition. It is not a weight-management or type 2 diabetes medication. No GLP-2 medication is approved for the indications GLP-1 medications cover.

Why are both peptides in the news?

GLP-1 receptor agonists have been in the news because of breakthrough weight-management outcomes. GLP-2 has stayed in a small therapeutic niche. The shared "GLP" prefix and proglucagon biology cause frequent confusion in consumer search behavior.

Does genetic testing cover both pathways?

The Precision Peptide Genetic Test analyzes pathway-level variants in GLP1R, FTO, and MC4R and other genes that shape baseline GLP-1 biology. The test is GLP-1 pathway focused, since that is the pathway most relevant to the weight-management and type 2 diabetes context PlexusDx supports.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education